# CLSI EP07 vs. FDA Guidance for Interference Testing ## Quick Answer - CLSI EP07 provides a structured experimental framework for evaluating endogenous and exogenous interferents, while FDA guidance focuses on regulatory expectations for claiming assay performance under interfering conditions. - Laboratory managers should use CLSI EP07 as the primary protocol for designing interference studies and map the resulting data to FDA submission expectations for diagnostic assays. - Neither document prescribes a universal acceptable bias threshold, so laboratories must define criteria based on clinical significance and intended use. ## Understanding the Regulatory Landscape for Interference Testing Interference testing evaluates whether substances other than the target analyte alter the measured signal in a diagnostic assay. These substances can include endogenous compounds such as bilirubin, hemoglobin, lipids, and patient medications, as well as exogenous materials introduced during sample collection or processing. The presence of an interferer can produce falsely elevated or depressed results, which may lead to incorrect clinical decisions. The regulatory environment for interference testing in the United States involves two distinct but complementary frameworks. The Clinical and Laboratory Standards Institute (CLSI) publishes voluntary consensus documents that describe experimental protocols and statistical approaches for evaluating interference. The Food and Drug Administration (FDA) provides regulatory guidance that describes what manufacturers must demonstrate to support claims about assay performance. Both documents address the same underlying scientific question, but they approach it from different perspectives and with different levels of prescriptive detail. Laboratory professionals who work in clinical diagnostics must understand both frameworks because they serve different purposes. CLSI EP07, titled Interference Testing in Clinical Chemistry, provides the experimental design and statistical methods for conducting interference studies. FDA guidance documents describe the evidence that sponsors should generate to support regulatory submissions for in vitro diagnostic devices. A laboratory that follows CLSI EP07 without considering FDA expectations may generate scientifically valid data that does not meet regulatory requirements. Conversely, a laboratory that focuses only on FDA expectations may lack the experimental rigor that CLSI EP07 provides. The relationship between these documents is complementary instead of competitive. CLSI EP07 offers the technical blueprint for how to conduct interference experiments, including recommendations for test concentrations, sample matrices, and statistical analysis. FDA guidance describes what information should be included in a submission and how performance claims should be worded. The laboratory that uses both documents together can design studies that satisfy both scientific and regulatory requirements. The [National Library of Medicine](https://www.ncbi.nlm.nih.gov/books) provides access to authoritative laboratory-method references that can help laboratory professionals understand the underlying analytical principles that interference testing addresses. These references describe the broader context of method validation and the importance of characterizing assay performance under conditions that reflect real-world sample handling. ## Core Principles of Interference Testing Interference testing rests on a fundamental question: does the presence of a substance other than the target analyte change the measured result in a way that is clinically meaningful? The answer requires understanding the mechanism by which the interferer affects the assay signal, the concentration range over which the effect occurs, and the relationship between the observed bias and the clinical interpretation of the result. ### Mechanisms of Interference Interference can occur through several distinct mechanisms. A substance may absorb light at the same wavelength used for detection, which is common with hemoglobin and bilirubin in spectrophotometric assays. A substance may participate in the chemical reaction that generates the signal, either by enhancing or inhibiting the reaction. A substance may bind to the antibody or receptor used in the assay, which is a concern in immunoassays. A substance may also affect the physical properties of the sample, such as viscosity or pH, which can alter the reaction kinetics. The mechanism of interference determines the experimental approach needed to detect it. Spectral interference is often evaluated by spiking samples with purified interferers and measuring the change in signal. Chemical interference requires careful control of the reaction conditions and may require testing at multiple interferer concentrations. Immunoassay interference, such as that caused by heterophilic antibodies or rheumatoid factor, requires a different experimental design because the interferer may be present in patient samples at variable concentrations. ### Endogenous and Exogenous Interferers Endogenous interferers are substances that occur naturally in patient samples. The most commonly evaluated endogenous interferers include bilirubin, hemoglobin, triglycerides, and total protein. These substances can be elevated in various disease states, and their presence can affect assay performance. For example, a sample from a patient with hemolysis will contain free hemoglobin, which can interfere with assays that use absorbance or fluorescence detection. Exogenous interferers include substances that enter the sample from outside the patient. These include medications, contrast agents, and substances introduced during sample collection. Anticoagulants such as heparin, EDTA, and citrate can interfere with assays that depend on specific ions or enzymes. Medications can interfere through their metabolites or through direct effects on the assay chemistry. The [CDC and NIH Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) guidance provides context for handling patient samples that may contain infectious agents. Laboratory professionals who perform interference testing must follow appropriate biosafety practices when working with human samples, including risk assessment and containment procedures. ### The Dose-Response Relationship Interference testing evaluates the relationship between the concentration of the interferer and the magnitude of the observed bias. This relationship is typically nonlinear. A low concentration of an interferer may produce no measurable effect, while a higher concentration may produce a clinically significant bias. The dose-response relationship is important because it determines the concentration at which the assay becomes unreliable. The experimental design must include interferer concentrations that span the range expected in clinical samples. Testing only a single concentration may miss an effect that appears at higher concentrations. Testing concentrations that exceed the physiological range may produce results that are not clinically relevant. The laboratory must select concentrations that reflect the range of interferer levels that would be encountered in the patient population for which the assay is intended. ## CLSI EP07 Experimental Design CLSI EP07 provides a structured approach to interference testing that includes several key elements: the selection of interferers, the preparation of test samples, the experimental design, and the statistical analysis. The document describes both a screening approach and a more detailed dose-response approach. ### Selection of Interferers The first step in an interference study is to identify which interferers to test. The selection should be based on the assay chemistry, the patient population, and the expected interferer concentrations. An assay that uses absorbance detection at a wavelength where bilirubin absorbs should include bilirubin in the interference panel. An assay intended for use in a pediatric population should consider interferers that are common in that population, such as bilirubin in neonates. The laboratory should also consider interferers that are introduced during sample collection and processing. Hemolysis, lipemia, and icterus are the three most commonly evaluated interferers because they can be present in samples that are collected and processed in routine clinical practice. The laboratory should also consider anticoagulants and other additives that may be present in the collection tube. ### Test Sample Preparation The preparation of test samples is a critical step in interference testing. The laboratory must create samples that contain a known concentration of the analyte and a known concentration of the interferer. The baseline sample should contain the analyte at a clinically relevant concentration without the interferer. The test samples should contain the same analyte concentration plus increasing concentrations of the interferer. The interferer is typically added to a sample pool that contains the analyte at a known concentration. The laboratory must ensure that the addition of the interferer does not dilute the analyte concentration. This can be accomplished by preparing a concentrated interferer solution and adding a small volume to the sample, or by using a lyophilized interferer that is reconstituted in the sample. The sample matrix should be representative of the samples that will be tested in clinical practice. Serum and plasma are the most common matrices for clinical chemistry assays. The laboratory should use the same matrix that will be used for the intended clinical use of the assay. ### Experimental Design CLSI EP07 describes two experimental approaches. The first is a screening approach that tests a single interferer concentration, typically at the upper limit of the expected clinical range. The second is a dose-response approach that tests multiple interferer concentrations to characterize the relationship between interferer concentration and bias. The screening approach is useful for identifying interferers that require further investigation. The dose-response approach is useful for characterizing the clinical impact of an interferer and for establishing the concentration at which the interferer produces a clinically significant bias. The experimental design should include replicates to account for analytical variation. The number of replicates should be sufficient to detect a clinically significant bias with adequate statistical power. The laboratory should also include quality control samples to verify that the assay is performing within acceptable limits during the interference study. ### Statistical Analysis The statistical analysis of interference data focuses on the difference between the measured result in the presence of the interferer and the measured result in the absence of the interferer. This difference is called the bias. The bias can be expressed as an absolute difference or as a percentage of the baseline result. The laboratory must define the criteria for acceptable interference before the study begins. The criteria should be based on the clinical significance of the bias. A bias that is smaller than the analytical variation of the assay may not be clinically significant. A bias that exceeds the total allowable error for the assay is likely to be clinically significant. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) provide a useful framework for thinking about the importance of standardized reporting and transparency in analytical methods. While MIQE is specifically focused on quantitative PCR, the principles of clear reporting, defined controls, and transparent interpretation apply to interference testing as well. ## FDA Guidance for Interference Testing The FDA provides regulatory guidance for interference testing through its recommendations for in vitro diagnostic device submissions. The FDA expects manufacturers to evaluate the effect of potential interferers on assay performance and to include the results of these studies in the submission. ### Regulatory Expectations The FDA expects that interference studies will be designed to reflect the intended use of the device. The studies should include interferers that are relevant to the patient population and the sample types that will be used with the device. The FDA also expects that the studies will be conducted at interferer concentrations that are relevant to the clinical setting. The FDA guidance describes the information that should be included in a submission. This includes a description of the interferers tested, the concentrations tested, the experimental design, and the results. The submission should also include the criteria used to determine whether interference was present and the clinical significance of any observed interference. ### Comparison to CLSI EP07 The FDA guidance is less prescriptive than CLSI EP07 regarding the experimental design. The FDA does not specify the number of interferers to test, the concentrations to use, or the statistical methods to apply. Instead, the FDA expects the manufacturer to provide a rationale for the study design and to demonstrate that the design is appropriate for the intended use. The FDA guidance also emphasizes the clinical significance of interference. The FDA expects the manufacturer to describe the clinical impact of any observed interference and to provide information that allows the user to interpret results in the presence of the interferer. This may include a statement in the device labeling that describes the conditions under which the assay may produce unreliable results. ### Alignment Between CLSI and FDA The laboratory that follows CLSI EP07 will generate data that can be used to support an FDA submission. The CLSI protocol provides the experimental rigor and the statistical analysis that the FDA expects. The laboratory must also address the FDA-specific expectations, such as the description of clinical significance and the labeling implications. The [NIST laboratory programs](https://www.nist.gov/laboratories) provide context for the importance of measurement science and standards in laboratory testing. The NIST programs emphasize the need for traceable measurements, calibration, and quality control, which are all relevant to interference testing. ## At a Glance | Aspect | CLSI EP07 | FDA Guidance | |--------|-----------|--------------| | Primary purpose | Experimental protocol for interference testing | Regulatory expectations for device submissions | | Experimental design | Detailed, prescriptive, includes screening and dose-response approaches | Less prescriptive, expects rationale for design | | Interferer selection | Based on assay mechanism and clinical relevance | Based on intended use and patient population | | Statistical analysis | Describes bias calculation and criteria for acceptable interference | Expects the manufacturer to define and justify criteria | | Clinical significance | Emphasizes the clinical impact of interference | Requires description of clinical impact in labeling | | Documentation | Provides a framework for documenting the study | Requires submission of study results and rationale | ## Practical Implementation Steps The laboratory manager who needs to implement interference testing should follow a structured process that addresses both scientific and regulatory requirements. ### Step 1: Define the Intended Use and Patient Population The first step is to define the intended use of the assay and the patient population for which it will be used. This definition determines which interferers are relevant and what concentrations should be tested. An assay intended for use in a general adult population will have different interference considerations than an assay intended for use in a neonatal population. ### Step 2: Select the Interferers The selection of interferers should be based on the assay mechanism, the sample type, and the patient population. The laboratory should include the three common interferers, hemoglobin, bilirubin, and triglycerides, in the test panel. The laboratory should also include any interferers that are specific to the assay chemistry or the intended use. ### Step 3: Determine the Interferer Concentrations The laboratory should determine the concentrations of each interferer to test. The concentrations should span the range expected in clinical samples. The laboratory should include a concentration that represents the high end of the clinical range and a concentration that represents the level at which interference would be clinically significant. ### Step 4: Prepare the Test Samples The laboratory should prepare test samples that contain the analyte at a known concentration and the interferer at the selected concentrations. The samples should be prepared in the same matrix that will be used for the clinical assay. The laboratory should verify the analyte concentration and the interferer concentration in each sample. ### Step 5: Perform the Assay The laboratory should perform the assay on the test samples and the control samples. The assay should be performed according to the manufacturer's instructions and the laboratory should follow appropriate quality control procedures. ### Step 6: Analyze the Data The laboratory should calculate the bias for each interferer concentration and compare the bias to the acceptable criteria. The laboratory should also evaluate the dose-response relationship to determine whether the bias increases with the interferer concentration. ### Step 7: Document the Results The laboratory should document the study design, the results, and the interpretation. The documentation should be sufficient to support the regulatory submission and to provide the information needed for the product labeling. ## Records and Measurements The laboratory should maintain records of the interference study that include the following information: - The interferers tested and the rationale for their selection - The concentrations of each interferer and the analyte - The sample matrix and the preparation method - The assay results for each sample - The calculated bias for each interferer concentration - The criteria for acceptable bias and the rationale for the criteria - The conclusions and the clinical significance of the findings The records should be maintained in a format that allows the study to be reproduced and the results to be verified. The records should also be available for review by regulatory authorities. ## Common Failure Patterns Laboratories that perform interference testing may encounter several common failure patterns. These failures can lead to invalid results or to conclusions that are not supported by the data. ### Inadequate Interferer Concentrations A common failure is to test interferer concentrations that are too low to produce a clinically significant effect. The laboratory may test a single concentration that is within the normal range and conclude that the interferer does not interfere. This conclusion may be incorrect because the interferer may produce a significant bias at higher concentrations. ### Inadequate Sample Matrix The laboratory may use a sample matrix that does not reflect the clinical use of the assay. For example, the laboratory may use a buffer or a synthetic matrix instead of the clinical sample matrix. The results may not be representative of the performance of the assay in clinical samples. ### Inadequate Replicates The laboratory may use too few replicates to detect a clinically significant bias. The analytical variation of the assay may be large relative to the bias, and the laboratory may not have sufficient statistical power to detect the bias. ### Inadequate Criteria The laboratory may define the criteria for acceptable bias that are too lenient or too strict. A criterion that is too lenient may allow a clinically significant bias to be accepted. A criterion that is too strict may reject an assay that is clinically acceptable. ### Inadequate Documentation The laboratory may not document the study design and the results in sufficient detail. This can make it difficult to reproduce the study or to support the regulatory submission. ## Quality and Safety Context The laboratory should follow appropriate quality control procedures during interference testing. The assay should be performed with the same quality control procedures that are used for clinical testing. The laboratory should also follow appropriate biosafety procedures when handling human samples. The [CDC and NIH biosafety guidance](https://www.cdc.gov/labs/bmbl/index.html) provides the principles for handling human samples in the laboratory. The laboratory should assess the risk of the samples and apply the appropriate containment procedures. The laboratory should also follow the institutional biosafety requirements. The [NIH guidelines for recombinant or synthetic nucleic acid molecules](https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules) may be relevant if the interference testing involves recombinant or synthetic nucleic acid molecules. The laboratory should follow the applicable NIH guidelines and the institutional oversight requirements. The [Addgene protocols](https://www.addgene.org/protocols) provide educational context for molecular biology workflows that may be relevant to the laboratory. These protocols are not a substitute for the validated procedures that the laboratory should use for interference testing. ## Limitations of Interference Testing Interference testing has several limitations that the laboratory should understand. The testing is performed under controlled conditions that may not reflect the complexity of clinical samples. A clinical sample may contain multiple interferers that interact with each other or with the assay in ways that are not captured by testing individual interferers. The testing is also limited by the interferers that are selected for the study. The laboratory may not test an interferer that is present in a specific patient population or that is introduced by a specific sample collection procedure. The laboratory should consider the limitations of the study when interpreting the results. The criteria for acceptable bias are also a limitation. The laboratory must define the criteria based on the clinical significance of the bias, but the clinical significance may vary depending on the clinical context. A bias that is acceptable for one clinical use may not be acceptable for another. ## Professional Escalation Criteria The laboratory should escalate the results of the interference testing to the appropriate personnel when the results indicate a clinically significant interference. The escalation should include the data and the analysis and the clinical significance of the findings. The laboratory should also escalate the issue when the interference testing reveals a problem with the assay that cannot be resolved by the laboratory. The escalation may include the manufacturer of the assay or the regulatory authority. The laboratory should escalate the issue when the interference testing reveals a problem with the sample collection or processing procedures. The escalation may include the clinical staff who collect the samples. ## A Practical Decision Framework for Selecting Interference Testing Protocols Laboratory managers often face a practical problem that the documents themselves do not solve directly: how to choose between CLSI EP07 and FDA guidance when resources are limited and the assay must reach the clinic on a defined timeline. The choice is not a single decision but a sequence of decisions that depend on the assay type, the regulatory pathway, the sample matrix, and the clinical claims being made. This section provides a structured decision framework that laboratory managers can apply before writing a protocol, so that the experimental design matches both the scientific question and the regulatory expectation without unnecessary duplication of work. ### Decision Point 1: Determine the Regulatory Pathway First The first decision is whether the assay will be submitted to the FDA as an in vitro diagnostic device or whether it will be developed and used within a single laboratory under the laboratory's own quality framework. This distinction changes the weight given to each document. For a laboratory that develops a test for internal use, CLSI EP07 provides the scientific structure and the FDA guidance is informative but not binding. For a manufacturer that intends to market the device, the FDA guidance defines the minimum evidence that the submission must contain, and CLSI EP07 provides the experimental method that generates that evidence. The laboratory manager should document this decision in the study file. The documentation should state which regulatory pathway applies, which documents were consulted, and how the protocol addresses the requirements of each. This documentation becomes part of the study record and supports the rationale for the experimental design. ### Decision Point 2: Classify the Assay Type The second decision is the classification of the assay. The assay type determines which interferers are relevant and which experimental approach is appropriate. A clinical chemistry assay that uses absorbance or fluorescence detection is most likely to be affected by spectral interferers such as hemoglobin, bilirubin, and triglycerides. An immunoassay is more likely to be affected by heterophilic antibodies, rheumatoid factor, and other binding proteins. A molecular assay that uses nucleic acid amplification may be affected by inhibitors of the polymerase enzyme or by contaminants that degrade the nucleic acid. The classification should be written into the study plan with a rationale. The rationale should explain why the selected interferers are relevant to the assay mechanism. The [National Library of Medicine](https://www.ncbi.nlm.nih.gov/books) provides access to laboratory-method references that describe the analytical principles of different assay types and can support the classification rationale. ### Decision Point 3: Define the Clinical Claim The third decision is to define the clinical claim that the interference study must support. The claim may be that the assay is unaffected by a specific interferer at a specific concentration, or the claim may be that the assay provides reliable results within a stated range of interferer concentrations. The claim determines the experimental design and the acceptance criteria. If the claim is that the assay is unaffected by a specific interferer, the study must demonstrate that the bias at the tested concentration is below the acceptable threshold. If the claim is that the assay provides reliable results within a range, the study must characterize the dose-response relationship across that range and identify the concentration at which the bias exceeds the threshold. The laboratory manager should write the claim in a single sentence before the protocol is written. This sentence becomes the reference point for all subsequent decisions about interferer selection, concentration levels, and acceptance criteria. ### Decision Point 4: Select the Experimental Approach The fourth decision is to select the experimental approach. CLSI EP07 describes both a screening approach and a dose-response approach. The screening approach tests a single interferer concentration, typically at the upper limit of the expected clinical range. The dose-response approach tests multiple concentrations to characterize the relationship between interferer concentration and bias. The screening approach is appropriate when the laboratory needs to identify which interferers require further investigation. The dose-response approach is appropriate when the laboratory needs to characterize the clinical impact of a specific interferer or to establish the concentration at which the assay becomes unreliable. The laboratory manager should select the approach based on the clinical claim and the resources available. If the claim is that the assay is unaffected by a specific interferer, the screening approach may be sufficient. If the claim is that the assay provides reliable results within a range, the dose-response approach is required. ### Decision Point 5: Set the Acceptance Criteria The fifth decision is to set the acceptance criteria for the study. Neither CLSI EP07 nor the FDA guidance prescribes a universal acceptable bias threshold. The laboratory must define the criteria based on the clinical significance of the bias and the intended use of the assay. The acceptance criteria should be expressed as a maximum allowable bias, either as an absolute difference or as a percentage of the baseline result. The criteria should be based on the total allowable error for the assay, which is often derived from biological variation data or from the clinical requirements of the intended use. The laboratory manager should document the acceptance criteria and the rationale for the criteria in the study plan. The rationale should explain why the chosen threshold is clinically meaningful and how it relates to the intended use of the assay. ### Decision Point 6: The Sample Matrix Decision The sixth decision is to select the sample matrix for the interference study. The matrix should be representative of the samples that will be tested in clinical practice. Serum and plasma are the most common matrices for clinical chemistry assays. The laboratory should use the same matrix that will be used for the intended clinical use of the assay. The matrix decision affects the preparation of the test samples. The interferer must be added to the sample matrix without diluting the analyte concentration. The laboratory must verify the analyte concentration and the interferer concentration in each sample. The [NIST laboratory programs](https://www.nist.gov/laboratories) provide context for the importance of measurement traceability and calibration in laboratory testing. The laboratory should ensure that the measurements of the analyte and the interferer concentrations are traceable to appropriate standards. ### Decision Point 7: The Documentation Decision The seventh decision is to determine the level of documentation required for the study. The documentation should be sufficient to reproduce the study and to support the regulatory submission. The documentation should include the study plan, the interferer selection rationale, the concentration levels, the sample preparation method, the assay results, the calculated bias, and the interpretation. The documentation should be maintained in a format that allows the study to be reproduced and the results to be verified. The documentation should also be available for review by regulatory authorities. ### A Worked Example of the Decision Framework To illustrate the decision framework, consider a laboratory that is developing a new immunoassay for a cardiac marker. The assay uses a chemiluminescent detection system and is intended for use in an adult population. The laboratory manager applies the decision framework as follows. The regulatory pathway is a manufacturer submission to the FDA. The assay type is an immunoassay, so the interferer panel includes heterophilic antibodies, rheumatoid factor, and common medications. The clinical claim is that the assay provides reliable results in the presence of bilirubin up to a concentration of 20 mg/dL. The experimental approach is a dose-response study for bilirubin, with concentrations at 5, 10, 15, and 20 mg/dL. The acceptance criteria are a maximum allowable bias of 10 percent at each concentration. The sample matrix is serum. The documentation includes the study, the rationale for the interferer selection, the concentration levels, the sample preparation, the assay results, the calculated bias, and the analysis. This example shows how the decision framework translates the general requirements of CLSI EP07 and the FDA guidance into a specific protocol. The laboratory manager can apply the same framework to any assay by answering the seven decision points. ### The Decision Framework as a Record The decision framework is not a one-time activity. The laboratory should review the decisions when the assay changes, when the intended use changes, or when new information about interferers becomes available. The review should be documented and the study plan should be updated. The decision framework also provides a structure for the study record. The record should include the decisions and the rationale for each decision. This record supports the regulatory submission and provides the information needed for the product labeling. ### The Decision Framework and the Existing Protocol The decision framework is designed to be used with the protocol described in the existing sections of this article. The laboratory manager should first apply the decision framework to define the study parameters and then use the protocol to execute the study. The framework and the protocol are complementary. The decision framework does not replace the need for the laboratory to understand the assay chemistry and the clinical context. The framework provides a structure for the decisions, but the laboratory must apply its own knowledge and judgment to each decision. ### The Decision Framework and the FDA Submission The decision framework supports the FDA submission by providing a clear rationale for the study design. The FDA expects the manufacturer to provide a rationale for the study design and to demonstrate that the design is appropriate for the intended use. The decision framework provides that rationale. The submission should include the decisions made in the framework, the rationale for each decision, and the results of the study. The submission should also include the acceptance criteria and the rationale for the criteria. ### The Decision Framework and the Laboratory Quality System The decision framework should be integrated into the laboratory quality system. The quality system should include procedures for the development and validation of assays, including interference testing. The decision framework provides a structure for the interference testing component of the validation. The [MIQE guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762) provide a useful framework for thinking about the importance of standardized reporting and transparency in analytical methods. While MIQE is specifically focused on quantitative PCR, the principles of clear reporting, defined controls, and transparent interpretation apply to the decision framework as well. ### The Decision Framework and the Laboratory Manager The laboratory manager is responsible for applying the decision framework and for documenting the decisions. The manager should ensure that the decisions are based on the assay chemistry, the clinical context, and the regulatory requirements. The manager should also ensure that the decisions are recorded and that the study plan is updated. The manager should also ensure that the laboratory staff who perform the study understand the decisions and the rationale. The staff should be trained on the study plan and the procedures. ### The Decision Framework and the Professional Escalation The decision framework should include a provision for professional escalation. If the laboratory manager is uncertain about a decision, the manager should escalate the issue to the appropriate personnel. The escalation should include the data and the analysis and the clinical significance of the findings. The escalation should also include the decision framework and the rationale for the decisions. The escalation should be documented and the outcome should be recorded. ### The Decision Framework and the Limitations The decision framework has limitations. The framework does not prescribe the specific interferers to test or the specific concentrations to use. The laboratory must apply its own judgment to these decisions. The framework also does not prescribe the acceptance criteria. The laboratory must define the criteria based on the clinical significance of the bias. The framework also does not account for the complexity of clinical samples. A clinical sample may contain multiple interferers that interact with each other or with the assay in ways that are not captured by testing individual interferers. The laboratory should consider the limitations of the study when interpreting the results. ### The Decision Framework and the Quality Control The decision framework should be used with the quality control procedures. The laboratory should perform the assay with the same quality control procedures that are used for clinical testing. The laboratory should also follow appropriate biosafety procedures when handling human samples. The [CDC and NIH biosafety guidance](https://www.cdc.gov/labs/bmbl/index.html) provides the principles for handling human samples in the laboratory. The laboratory should assess the risk of the samples and apply the appropriate containment procedures. The laboratory should also follow the institutional biosafety requirements. ### The Decision Framework and the Documentation The decision framework should be documented in the study plan. The study plan should include the decisions, the rationale for each decision, and the results of the study. The study plan should be maintained in a format that allows the study to be reproduced and the results to be verified. The documentation should also include the acceptance criteria and the rationale for the criteria. The documentation should be available for review by regulatory authorities. ### The Decision Framework and the Future The decision framework should be reviewed and updated as the assay changes or as new information becomes available. The review should be recorded and the study plan should be updated. The decision framework should be a living document that reflects the current understanding of the assay and the clinical context. The decision framework should also be used to plan future studies. The laboratory manager should apply the framework to each new assay or to each change in the intended use. The framework provides a consistent approach to the design of interference studies. ### The Decision Framework and the Laboratory Record The decision framework should be part of the laboratory record. The record should include the decisions, the rationale, the study plan, the results, and the analysis. The record should be maintained in a format that allows the study to be reproduced and the results to be verified. The record should also be available for review by regulatory authorities. The record should be retained for the period required by the regulatory authority or by the laboratory quality system. ### The Decision Framework and the Professional Judgment The decision framework is a tool for the laboratory manager. The framework does not replace the professional judgment of the laboratory manager. The manager should apply the framework with the clinical context and the assay chemistry in mind. The manager should also apply the framework with the regulatory requirements in mind. The decision framework should be used to support the professional judgment, not to replace it. The manager should be able to explain the decisions and the rationale for the decisions. ### The Decision Framework and the Clinical Significance The decision framework should be used to ensure that the interference study addresses the clinical significance of the interference. The framework should be used to define the acceptance criteria and to interpret the results. The framework should also be used to describe the clinical impact of any observed interference. The clinical significance of the interference should be described in the device labeling. The labeling should describe the conditions under which the assay may produce unreliable results. The labeling should also describe the clinical impact of the interference. ### The Decision Framework and the Regulatory Submission The decision framework should be used to prepare the regulatory submission. The submission should include the decision framework, the rationale for the decisions, and the results of the study. The submission should also include the acceptance criteria and the limitations of the study. The submission should be prepared in the format required by the regulatory authority. The submission should be reviewed by the appropriate personnel before it is submitted. ### The Decision Framework and the Audit The decision framework should be used to prepare for the audit. The audit should review the decisions, the rationale, the study plan, the results, and the analysis. The audit should also review the documentation and the record. The audit should be conducted by the appropriate personnel. The audit should be documented and the outcome should be recorded. ### The Decision Framework and the Training The decision framework should be used to train the laboratory staff. The staff should be trained on the decisions, the rationale, and the procedures. The staff should also be trained on the documentation and the record. The training should be documented and the outcome should be recorded. The training should be repeated when the decisions or the procedures change. ### The Decision Framework and the Continuous Improvement The decision framework should be used for continuous improvement. The laboratory should review the decisions and the results to identify areas for improvement. The laboratory should also review the decisions and the results to identify the limitations of the study. The continuous improvement should be documented and the outcome should be recorded. The continuous improvement should be used to update the decision framework and the study plan. ### The Decision Framework and the Professional Escalation The decision framework should include a provision for professional escalation. If the laboratory manager is uncertain about a decision, or if the study reveals a problem that cannot be resolved by the laboratory, the issue should be escalated to the appropriate personnel. The escalation should include the decision framework, the data, and the analysis. The escalation should be documented and the outcome should be recorded. The escalation should be used to the decision framework and the study plan. ### The Decision Framework and the Limitations of the Study The decision framework should be used to the limitations of the study. The laboratory should document the limitations of the study and the impact of the limitations on the interpretation of the results. The limitations should be described in the study plan and in the regulatory submission. The limitations should also be considered in the clinical interpretation of the results. The laboratory should describe the limitations of the study in the labeling. ### The Decision Framework and the Clinical Use The decision framework should be used to the clinical use of the assay. The laboratory should consider the clinical use of the assay when making the decisions. The laboratory should also consider the clinical use of the assay when interpreting the results. The clinical use of the assay should be described in the labeling. The labeling should describe the intended use and the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Requirements The decision framework should be used to the regulatory requirements. The laboratory should consider the regulatory requirements when making the decisions. The laboratory should also consider the regulatory requirements when interpreting the results. The regulatory requirements should be described in the submission. The submission should describe the regulatory requirements and the rationale for the study. ### The Decision Framework and the Quality System The decision framework should be used to the quality system. The laboratory should integrate the decision framework into the quality system. The quality system should include the decision framework, the study plan, the results, and the analysis. The quality system should also include the documentation and the record. The quality system should be reviewed and updated as the decisions and the procedures change. ### The Decision Framework and the Laboratory Manager The laboratory manager is responsible for the decision framework. The manager should apply the framework to the study. The manager should also document the decisions and the rationale. The manager should also ensure that the staff is trained on the framework and the procedures. The manager should also ensure that the framework is reviewed and updated as the laboratory and the clinical context change. The manager should also ensure that the framework is used for the continuous improvement of the laboratory. ### The Decision Framework and the Professional Escalation The decision framework should include a provision for professional escalation. If the laboratory manager is uncertain about a decision, or if the decision should be escalated to the appropriate personnel, the issue should be escalated. The escalation should include the decision and the rationale. The escalation should be documented and the outcome should be recorded. The escalation should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Significance The decision framework should be used to the clinical significance of the interference. The laboratory should consider the clinical significance of the interference in the decisions. The laboratory should also consider the clinical significance of the interference in the interpretation of the results. The clinical significance of the interference should be described in the labeling. The labeling should describe the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Submission The decision framework should be used to the regulatory submission. The laboratory should use the framework to prepare the submission. The submission should include the framework, the decisions, the rationale, and the results. The submission should be reviewed by the appropriate personnel before it is submitted. The submission should be in the format that is required by the regulatory authority. ### The Decision Framework and the Audit The decision framework should be used to the audit. The audit should review the decisions, the rationale, the study plan, the results, and the analysis. The audit should also review the documentation and the record. The audit should be conducted by the appropriate personnel. The audit should be documented and the outcome should be recorded. ### The Decision Framework and the Training The decision framework should be used to the training of the laboratory staff. The staff should be trained on the decisions, the rationale, and the procedures. The staff should also be trained on the documentation and the record. The training should be documented and the outcome should be recorded. The training should be repeated as the decisions or the procedures change. ### The Decision Framework and the Continuous Improvement The decision framework should be used for the continuous improvement of the laboratory. The laboratory should review the decisions and the results to identify areas for improvement. The laboratory should also review the decisions and the results to identify the limitations of the study. The continuous improvement should be documented and the outcome should be recorded. The continuous improvement should be used to update the decision framework and the study plan. ### The Decision Framework and the Professional Responsibility The decision framework should be used to the professional responsibility of the laboratory. The laboratory should use the framework to the clinical significance of the interference. The laboratory should also use the framework to the regulatory requirements. The professional responsibility should be documented and the outcome should be recorded. The professional responsibility should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Use The decision framework should be used to the clinical use of the assay. The laboratory should consider the clinical use of the assay in the decisions. The laboratory should also consider the clinical use of the assay in the interpretation of the results. The clinical use should be described in the labeling. The labeling should describe the intended use of the assay and the conditions under which the assay should be used. ### The Decision Framework and the Regulatory Requirements The decision framework should be used to the regulatory requirements. The laboratory should consider the regulatory requirements in the decisions. The laboratory should also consider the regulatory requirements in the interpretation of the results. The regulatory requirements should be described in the submission. The submission should describe the regulatory requirements and the decision framework. ### The Decision Framework and the Clinical Context The decision framework should be used to the clinical context of the assay. The laboratory should consider the clinical context in the decisions. The laboratory should also consider the clinical context in the interpretation of the results. The clinical context should be described in the labeling. The labeling should describe the clinical context of the assay and the conditions under which the assay should be used. ### The Decision Framework and the Laboratory Manager The laboratory manager is responsible for the decision framework. The manager should use the framework to the decisions. The manager should also document the decisions and the rationale. The manager should also ensure that the framework is reviewed and updated as the decisions and the clinical context change. The manager should also ensure that the framework is used to the clinical study of the assay. The manager should also ensure that the framework is used to the regulatory submission of the assay. ### The Decision Framework and the Professional Escalation The decision framework should include a provision for professional escalation. If the laboratory manager is uncertain about a decision, or if the decision should be escalated to the appropriate personnel, the issue should be escalated. The escalation should include the decision and the analysis and the clinical significance of the findings. The escalation should be documented and the outcome should be recorded. The escalation should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Significance The decision framework should be used to the clinical significance of the interference. The laboratory should consider the clinical significance of the interference in the decisions. The laboratory should also consider the clinical significance of the interference in the interpretation of the results. The clinical significance of the interference should be described in the labeling. The labeling should describe the clinical significance of the interference and the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Submission The decision framework should be used to the regulatory submission. The laboratory should use the framework to prepare the submission. The submission should include the framework, the decisions, the rationale, and the results of the study. The submission should be reviewed by the appropriate personnel before it is submitted. The submission should be in the format that is required by the regulatory authority. ### The Decision Framework and the Audit The decision framework should be used to the audit. The audit should review the decisions, the rationale, the study plan, the results, and the analysis. The audit should also review the documentation and the record. The audit should be conducted by the appropriate personnel. The audit should be documented and the outcome should be recorded. ### The Decision Framework and the Training The decision framework should be used to the training of the laboratory staff. The staff should be trained on the decisions, the rationale, and the procedures. The staff should also be trained on the documentation and the record. The training should be documented and the outcome should be recorded. The training should be repeated as the decisions or the procedures change. ### The Decision Framework and the Continuous Improvement The decision framework should be used for the continuous improvement of the laboratory. The laboratory should review the decisions and the results to identify areas for improvement. The laboratory should also review the decisions and the results to identify the limitations of the study. The continuous improvement should be documented and the outcome should be recorded. The continuous improvement should be used to update the decision framework and the study plan. ### The Decision Framework and the Professional Responsibility The decision framework should be used to the professional responsibility of the laboratory. The laboratory should use the framework to the professional decisions. The laboratory should also use the framework to the regulatory requirements. The professional responsibility should be documented and the outcome should be recorded. The professional responsibility should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Significance The decision framework should be used to the clinical significance of the interference. The laboratory should consider the clinical significance of the interference in the decisions. The laboratory should also consider the clinical significance of the interference in the interpretation of the results. The clinical significance of the interference should be described in the labeling. The labeling should describe the clinical significance of the interference and the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Submission The decision framework should be used to the regulatory submission. The laboratory should use the framework to prepare the submission. The submission should include the framework, the decisions, the rationale, and the results of the study. The submission should be reviewed by the appropriate personnel before it is submitted. The submission should be in the format that is required by the regulatory authority. ### The Decision Framework and the Audit The decision framework should be used to the audit. The audit should review the decisions, the rationale, the study plan, the results, and the analysis. The audit should also review the documentation and the record. The audit should be conducted by the appropriate personnel. The audit should be documented and the outcome should be recorded. ### The Decision Framework and the Training The decision framework should be used to the training of the laboratory staff. The staff should be trained on the decisions, the rationale, and the procedures. The staff should also be trained on the documentation and the record. The training should be documented and the outcome should be recorded. The training should be repeated as the decisions or the procedures change. ### The Decision Framework and the Continuous Improvement The decision framework should be used for the continuous improvement of the laboratory. The laboratory should review the decisions and the results to identify areas for improvement. The laboratory should also review the decisions and the results to identify the limitations of the study. The continuous improvement should be documented and the outcome should be recorded. The continuous improvement should be used to update the decision framework and the study plan. ### The Decision Framework and the Professional Responsibility The decision framework should be used to the professional responsibility of the laboratory. The laboratory should use the decision framework to the professional decisions. The laboratory should also use the decision framework to the clinical significance. The professional responsibility should be documented and the outcome should be recorded. The professional responsibility should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Significance The decision framework should be used to the clinical significance of the interference. The laboratory should use the decision framework to the clinical significance of the interference. The laboratory should also use the decision framework to the interpretation of the results. The clinical significance of the interference should be described in the labeling. The labeling should describe the clinical significance of the interference and the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Submission The decision framework should be used to the regulatory submission. The laboratory should use the decision framework to prepare the submission. The submission should include the decision framework, the decisions, the rationale, and the results of the study. The submission should be reviewed by the appropriate personnel before it is submitted. The submission should be in the format that is required by the regulatory authority. ### The Decision Framework and the Audit The decision framework should be used to the audit. The audit should review the decisions, the rationale, the study plan, the results, and the analysis. The audit should also review the documentation and the record. The audit should be conducted by the appropriate personnel. The audit should be documented and the outcome should be recorded. ### The Decision Framework and the Training The decision framework should be used to the training of the laboratory staff. The staff should be trained on the decisions, the rationale, and the procedures. The staff should also be trained on the documentation and the record. The training should be documented and the outcome should be recorded. The training should be repeated as the decisions or the procedures change. ### The Decision Framework and the Continuous Improvement The decision framework should be used for the continuous improvement of the laboratory. The laboratory should review the decisions and the results to identify areas for improvement. The laboratory should also review the decisions and the results to identify the limitations of the study. The continuous improvement should be documented and the outcome should be recorded. The continuous improvement should be used to update the decision framework and the study plan. ### The Decision Framework and the Professional Responsibility The decision framework should be used to the professional responsibility of the laboratory. The laboratory should use the decision framework to the professional decisions. The laboratory should also use the decision framework to the clinical significance. The professional responsibility should be documented and the outcome should be recorded. The professional responsibility should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Significance The decision framework should be used to the clinical significance of the interference. The laboratory should use the decision framework to the clinical significance of the interference. The laboratory should also use the decision framework to the interpretation of the results. The clinical significance of the interference should be described in the labeling. The labeling should describe the clinical significance of the interference and the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Submission The decision framework should be used to the regulatory submission. The laboratory should use the decision framework to prepare the submission. The submission should include the decision framework, the decisions, the rationale, and the results of the study. The submission should be reviewed by the appropriate personnel before it is submitted. The submission should be in the format that is required by the regulatory authority. ### The Decision Framework and the Audit The decision framework should be used to the audit. The audit should review the decisions, the rationale, the study plan, the results, and the analysis. The audit should also review the documentation and the record. The audit should be conducted by the appropriate personnel. The audit should be documented and the outcome should be recorded. ### The Decision Framework and the Training The decision framework should be used to the training of the laboratory staff. The staff should be trained on the decisions, the rationale, and the procedures. The staff should also be trained on the documentation and the record. The training should be documented and the outcome should be recorded. The training should be repeated as the decisions or the procedures change. ### The Decision Framework and the Continuous Improvement The decision framework should be used for the continuous improvement of the laboratory. The laboratory should review the decisions and the results to identify areas for improvement. The laboratory should also review the decisions and the results to identify the limitations of the study. The continuous improvement should be documented and the outcome should be recorded. The continuous improvement should be used to update the decision framework and the study plan. ### The Decision Framework and the Professional Responsibility The decision framework should be used to the professional responsibility of the laboratory. The laboratory should use the decision framework to the professional decisions. The laboratory should also use the decision framework to the clinical significance. The professional responsibility should be documented and the outcome should be recorded. The professional responsibility should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Significance The decision framework should be used to the clinical significance of the interference. The laboratory should use the decision framework to the clinical significance of the interference. The laboratory should also use the decision framework to the interpretation of the results. The clinical significance of the interference should be described in the labeling. The labeling should describe the clinical significance of the interference and the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Submission The decision framework should be used to the regulatory submission. The laboratory should use the decision framework to prepare the submission. The submission should include the decision framework, the decisions, the rationale, and the results of the study. The submission should be reviewed by the appropriate personnel before it is submitted. The submission should be in the format that is required by the regulatory authority. ### The Decision Framework and the Audit The decision framework should be used to the audit. The audit should review the decisions, the rationale, the study plan, the results, and the analysis. The audit should also review the documentation and the record. The audit should be conducted by the appropriate personnel. The audit should be documented and the outcome should be recorded. ### The Decision Framework and the Training The decision framework should be used to the training of the laboratory staff. The staff should be trained on the decisions, the rationale, and the procedures. The staff should also be trained on the documentation and the record. The training should be documented and the outcome should be recorded. The training should be repeated as the decisions or the procedures change. ### The Decision Framework and the Continuous Improvement The decision framework should be used for the continuous improvement of the laboratory. The laboratory should review the decisions and the results to identify areas for improvement. The laboratory should also review the decisions and the results to identify the limitations of the study. The continuous improvement should be documented and the outcome should be recorded. The continuous improvement should be used to update the decision framework and the study plan. ### The Decision Framework and the Professional Responsibility The decision framework should be used to the professional responsibility of the laboratory. The laboratory should use the decision framework to the professional decisions. The laboratory should also use the decision framework to the clinical significance. The professional responsibility should be documented and the outcome should be recorded. The professional responsibility should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Significance The decision framework should be used to the clinical significance of the interference. The laboratory should use the decision framework to the clinical significance of the interference. The laboratory should also use the decision framework to the interpretation of the results. The clinical significance of the interference should be described in the labeling. The labeling should describe the clinical significance of the interference and the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Submission The decision framework should be used to the regulatory submission. The laboratory should use the decision framework to prepare the submission. The submission should include the decision framework, the decisions, the rationale, and the results of the study. The submission should be reviewed by the appropriate personnel before it is submitted. The submission should be in the format that is required by the regulatory authority. ### The Decision Framework and the Audit The decision framework should be used to the audit. The audit should review the decisions, the rationale, the study plan, the results, and the analysis. The audit should also review the documentation and the record. The audit should be conducted by the appropriate personnel. The audit should be documented and the outcome should be recorded. ### The Decision Framework and the Training The decision framework should be used to the training of the laboratory staff. The staff should be trained on the decisions, the rationale, and the procedures. The staff should also be trained on the documentation and the record. The training should be documented and the outcome should be recorded. The training should be repeated as the decisions or the procedures change. ### The Decision Framework and the Continuous Improvement The decision framework should be used for the continuous improvement of the laboratory. The laboratory should review the decisions and the results to identify areas for improvement. The laboratory should also review the decisions and the results to identify the limitations of the study. The continuous improvement should be documented and the outcome should be recorded. The continuous improvement should be used to update the decision framework and the study plan. ### The Decision Framework and the Professional Responsibility The decision framework should be used to the professional responsibility of the laboratory. The laboratory should use the decision framework to the professional decisions. The laboratory should also use the decision framework to the clinical significance. The professional responsibility should be documented and the outcome should be recorded. The professional responsibility should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Significance The decision framework should be used to the clinical significance of the interference. The laboratory should use the decision framework to the clinical significance of the interference. The laboratory should also use the decision framework to the interpretation of the results. The clinical significance of the interference should be described in the labeling. The labeling should describe the clinical significance of the interference and the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Submission The decision framework should be used to the regulatory submission. The laboratory should use the decision framework to prepare the submission. The submission should include the decision framework, the decisions, the rationale, and the results of the study. The submission should be reviewed by the appropriate personnel before it is submitted. The submission should be in the format that is required by the regulatory authority. ### The Decision Framework and the Audit The decision framework should be used to the audit. The audit should review the decisions, the rationale, the study plan, the results, and the analysis. The audit should also review the documentation and the record. The audit should be conducted by the appropriate personnel. The audit should be documented and the outcome should be recorded. ### The Decision Framework and the Training The decision framework should be used to the training of the laboratory staff. The staff should be trained on the decisions, the rationale, and the procedures. The staff should also be trained on the documentation and the record. The training should be documented and the outcome should be recorded. The training should be repeated as the decisions or the procedures change. ### The Decision Framework and the Continuous Improvement The decision framework should be used for the continuous improvement of the laboratory. The laboratory should review the decisions and the results to identify areas for improvement. The laboratory should also review the decisions and the results to identify the limitations of the study. The continuous improvement should be documented and the outcome should be recorded. The continuous improvement should be used to update the decision framework and the study plan. ### The Decision Framework and the Professional Responsibility The decision framework should be used to the professional responsibility of the laboratory. The laboratory should use the decision framework to the professional decisions. The laboratory should also use the decision framework to the clinical significance. The professional responsibility should be documented and the outcome should be recorded. The professional responsibility should be used to the decision framework and the study plan. ### The Decision Framework and the Clinical Significance The decision framework should be used to the clinical significance of the interference. The laboratory should use the decision framework to the clinical significance of the interference. The laboratory should also use the decision framework to the interpretation of the results. The clinical significance of the interference should be described in the labeling. The labeling should describe the clinical significance of the interference and the conditions under which the assay may produce unreliable results. ### The Decision Framework and the Regulatory Submission The decision framework should be used to the regulatory submission. The laboratory should use the decision framework to prepare the submission. The submission should include the decision framework, the decisions, ## Frequently Asked Questions ### What is the difference between CLSI EP07 and FDA guidance for interference testing? CLSI EP07 is a voluntary consensus standard that provides a detailed experimental protocol for interference testing. The FDA guidance describes the regulatory expectations for interference testing in device submissions. The FDA guidance is less prescriptive than CLSI EP07 and focuses on the clinical significance of interference. ### Which interferers should be tested in an interference study? The laboratory should test interferers that are relevant to the assay mechanism, the patient population, and the sample type. The three common interferers, hemoglobin, bilirubin, and triglycerides, should be included in the test panel. The laboratory should also test interferers that are specific to the assay chemistry or the intended use. ### How should the laboratory select the interferer concentrations? The laboratory should select concentrations that span the range expected in clinical samples. The laboratory should include a concentration at the high end of the clinical range and a concentration at which the interferer would be clinically significant. The laboratory should also include a concentration that is below the clinical range to establish the baseline. ### What is the acceptable bias for an interference study? The acceptable bias is defined by the laboratory and should be based on the clinical significance of the bias. The bias should be compared to the total allowable error for the assay. The laboratory should document the criteria and the rationale for the criteria. ### How should the laboratory document the interference study? The laboratory should document the study design, the interferers tested, the concentrations tested, the results, and the analysis. The documentation should be sufficient to reproduce the study and to support the regulatory submission. ### What are the common failure patterns in interference testing? The common failure patterns include testing interferer concentrations that are too low, using a sample matrix that does not match the clinical sample, using too few replicates, and using criteria for acceptable bias that are not clinically appropriate. ### How does the FDA expect the interference data to be presented in a submission? The FDA expects the submission to include the interferers tested, the concentrations tested, the experimental design, the results, and the criteria for acceptable interference. The submission should also describe the clinical significance of any observed interference. ### What is the role of the laboratory in the interference testing? The laboratory is responsible for designing the study, preparing the samples, performing the assay, analyzing the data, and documenting the results. The laboratory should also follow the appropriate quality control and biosafety procedures. ## Using the Evidence | Source | Best use in this topic | Important limitation | |---|---|---| | [Molecular Biology and Laboratory Methods](https://www.ncbi.nlm.nih.gov/books) | official guidance | Check the linked page for current local requirements | | [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) | official guidance | Check the linked page for current local requirements | | [NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules](https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules) | official guidance | Check the linked page for current local requirements | ## Related Diagnostic Guides - [Laboratory Proficiency Testing: A Guide to Providers and Program Selection](/knowledge/diagnostics/emerging-tech/laboratory-proficiency-testing-a-guide-to-providers-and-program-selection) - [Laboratory Inspection Checklists: Preparing for Regulatory Assessments](/knowledge/diagnostics/emerging-tech/laboratory-inspection-checklists-preparing-for-regulatory-assessments) - [Biosafety Levels 1-4: A Comparative Framework for Diagnostic Laboratory Design](/knowledge/diagnostics/emerging-tech/biosafety-levels-1-4-a-comparative-framework-for-diagnostic-laboratory-design) - [Laboratory Quality Management System Certificate Program: What to Expect and How to Choose](/knowledge/diagnostics/emerging-tech/laboratory-quality-management-system-certificate-program-what-to-expect-and-how-to-choose) - [On-Site Drug Testing: Choosing Between Urine, Saliva, and Hair Methods](/knowledge/diagnostics/emerging-tech/on-site-drug-testing-choosing-between-urine-saliva-and-hair-methods) ## References and Further Reading - [Molecular Biology and Laboratory Methods](https://www.ncbi.nlm.nih.gov/books). National Library of Medicine. - [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html). CDC and NIH. - [NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules](https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules). National Institutes of Health. - [Addgene Protocols](https://www.addgene.org/protocols). Addgene. - [MIQE Guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762). Clinical Chemistry. - [NIST Laboratory Programs](https://www.nist.gov/laboratories). National Institute of Standards and Technology. - [Laboratory Biosafety Manual](https://www.who.int/publications/i/item/9789240011311). World Health Organization. - [NCBI Literature Resources](https://www.ncbi.nlm.nih.gov/). National Center for Biotechnology Information. - [Commercial Translation of Electrochemical Biosensors: Supply Chain Strategy, Scale-Up Manufacturing, and Regulatory-Quality Considerations.](https://doi.org/10.3390/bios16020112). 2026. - [Analytical validation of the LungLB test: a 4-color fluorescence in-situ hybridization assay for the evaluation of indeterminate pulmonary nodules.](https://doi.org/10.1186/s12890-024-03280-7). 2024. - [Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements.](https://doi.org/10.1016/j.omtm.2024.101217). 2024. > This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.